{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:50:09Z","timestamp":1793213409240,"version":"4.5.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    This study aims to assess the clinical efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression in adult patients through meta-analysis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    The PubMed, Embase, Cochrane Library, Clinical Trials, EU Clinical Trials Register, and International Clinical Trials Registry Platform were searched up to 25 October 2022. Only randomized controlled trials (RCTs) comparing the clinical outcomes of Trilaciclib and Trilaciclib plus chemotherapy for treating malignant cancers in adult patients were included. The primary outcome included the incidence of SN, FN, the DSN, and administration of ESAs, G-CSFs, and RBC or platelet transfusions, while the secondary outcomes included the risk of adverse events (AEs) and severe adverse events (SAEs).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    In total, four randomized controlled trials (RCTs) involving 345 patients with SCLC or breast cancer were included in this meta-analysis. Results showed that administration of Trilaciclib significantly reduced the occurrence of SN (19.3% vs. 42.2%, OR = 0.31), FN (3.22% vs. 6.72%, OR = 0.47), anemia (20.5% vs. 38.2%, OR = 0.38) and shortened the DSN during treatment. The proportion of patients receiving therapeutic use of ESAs (4.03% vs. 11.8%, OR = 0.31), G-CSF (37.0% vs. 53.5%, OR = 0.52), RBC transfusions (19.8% vs. 29.9%, OR = 0.56) was also statistically lower in the experimental group than in the control group. Meanwhile, the ORR, overall survival, and progress-free survival of the two groups were identical, and no negative impact of Trilaciclib on the clinical outcomes of chemotherapy treatments was found. Other chemotherapy-induced adverse events (AEs) and severe adverse events (SAEs) like diarrhea, fatigue, nausea, and vomiting were identical regardless of Trilaciclib usage.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Trilaciclib demonstrated its efficacy in reducing the occurrence of chemotherapy-induced myelosuppression and utilization of supportive care interventions without undermining the clinical benefits of chemotherapy regimens during treatment with an acceptable safety profile.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1157251","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:14:16Z","timestamp":1684973656000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"14","author":[{"given":"Jingyue","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/bloodadvances.2018030387","article-title":"Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update","volume":"3","author":"Bohlius","year":"2019","journal-title":"Blood Adv."},{"key":"B3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00520-019-04875-1","article-title":"Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer","volume":"28","author":"Crawford","year":"2020","journal-title":"Support Care Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/ijc.33705","article-title":"Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer","volume":"149","author":"D\u00f3mine G\u00f3mez","year":"2021","journal-title":"Int. J. Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1007\/s12325-020-01419-6","article-title":"Patient burden and real-world management of chemotherapy-induced myelosuppression: Results from an online survey of patients with solid tumors","volume":"37","author":"Epstein","year":"2020","journal-title":"Adv. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/13696998.2021.2020570","article-title":"Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: A retrospective analysis of electronic medical data from community cancer care providers","volume":"25","author":"Epstein","year":"2022","journal-title":"J. Med. Econ."},{"key":"B8","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1002\/cam4.4089","article-title":"Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials","volume":"10","author":"Ferrarotto","year":"2021","journal-title":"Cancer Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): Updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s12325-020-01538-0","article-title":"Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: Results from a randomized, double-blind, placebo-controlled phase II study","volume":"38","author":"Hart","year":"2021","journal-title":"Adv. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"eaal3986","DOI":"10.1126\/scitranslmed.aal3986","article-title":"Transient CDK4\/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion","volume":"9","author":"He","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.2147\/CMAR.S313045","article-title":"Myeloprotective effects of trilaciclib among patients with small cell lung cancer at increased risk of chemotherapy-induced myelosuppression: Pooled results from three phase 2, randomized, double-blind, placebo-controlled studies","volume":"13","author":"Hussein","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.21037\/jgo.2019.07.03","article-title":"Treatment delays during FOLFOX chemotherapy in patients with colorectal cancer: A multicenter retrospective analysis","volume":"10","author":"Kogan","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e000847","DOI":"10.1136\/jitc-2020-000847","article-title":"CDK4\/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy","volume":"8","author":"Lai","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"101206","DOI":"10.1016\/j.tranon.2021.101206","article-title":"Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer","volume":"14","author":"Powell","year":"2021","journal-title":"Transl. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1158\/1535-7163.MCT-18-1161","article-title":"Chemotherapy and CDK4\/6 inhibitors: Unexpected bedfellows","volume":"19","author":"Roberts","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S1470-2045(19)30616-3","article-title":"Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: A multicentre, randomised, open-label, phase 2 trial","volume":"20","author":"Tan","year":"2019","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1157251\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:14:19Z","timestamp":1684973659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1157251\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":19,"alternative-id":["10.3389\/fphar.2023.1157251"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1157251","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"article-number":"1157251"}}